-
Int Urol Nephrol : A study of the relationship between PCPE-1 and renal function in patients with multiple myeloma
Time of Update: 2022-10-12
PCPE-1 levels were not affected by other parameters throughout the study population and the MM group.
PCPE-1 levels were not affected by other parameters throughout the study population and the MM group.
PCPE-1 levels were not affected by other parameters throughout the study population and the MM group.
-
Expert interview: Professor Jiang Erlie related to the progress of autologous hematopoietic stem cell transplantation technology
Time of Update: 2022-10-12
Can you review what significant developments have been made in this area in recent years?Professor Jiang: The Blood Disease Hospital of the Chinese Academy of Medical Sciences is the earliest autologous hematopoietic stem cell transplant in China, dating back to 1986.
-
Nosocomial infection during ECMO
Time of Update: 2022-10-12
In a recent study, the immune response in the initial phase of V-AECMO showed the expression of immunosuppressive factors associated with an increased risk of infection in severely ill patients, which is significantly different from traditional therapeutic control [25].
-
Nat Commun: Nano-oxide graphyne can specifically kill DNMT3A mutant AML cells
Time of Update: 2022-10-12
On September 26, 2022, Qian Pengxu's research group at the School of Basic Medicine/Liangzhu Laboratory of Zhejiang University and Chen Chunying, a researcher at the National Center for Nanoscience, published an online article entitled "Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML.
-
Leukemia: Professor Ji Chunyan's team revealed a new target for the treatment of acute T lymphoblastic leukemia
Time of Update: 2022-10-12
Recently, the team of Professor Ji Chunyan from the Department of Hematology of Qilu Hospital of Shandong University, the team of Professor Li Jingxin from the School of Basic Medicine of Shandong University, and the team of Professor Baobing Zhao from the School of Pharmacy of Shandong University jointly published the title "Inhibition of the m6A Reader IGF2BP2 as a Strategy against Leukemia, an authoritative journal in the field of hematology and tumor.
-
Leukemia: Professor Ji Chunyan's team revealed a new target for the treatment of acute T lymphoblastic leukemia
Time of Update: 2022-10-12
Recently, the team of Professor Ji Chunyan from the Department of Hematology of Qilu Hospital of Shandong University, the team of Professor Li Jingxin from the School of Basic Medicine of Shandong University, and the team of Professor Baobing Zhao from the School of Pharmacy of Shandong University jointly published the title "Inhibition of the m6A Reader IGF2BP2 as a Strategy against Leukemia, an authoritative journal in the field of hematology and tumor.
-
Blood: Darafinil plus trametinib for relapsed/refractory BRAF V600E mutant hair cell leukemia
Time of Update: 2022-10-12
This paper reports the efficacy and safety of Dabrafenib plus trametinib in the treatment of patients with HCL who are positive for relapsed/refractory BRAF V600E mutations.
This paper reports the efficacy and safety of Dabrafenib plus trametinib in the treatment of patients with HCL who are positive for relapsed/refractory BRAF V600E mutations.
-
Blood: The new drug for leukemia! Recombinant Irving bacterium asparagine enzyme JZP458 Phase 2/3 test results are effective and safe!
Time of Update: 2022-10-12
AALL1931 is a Phase 2/3 study conducted in collaboration with the Pediatric Oncology Gene Association to evaluate the efficacy and safety of JZP458 (a recombinant erwinia asparaginase from a new expression platform) in patients with acute lymphoblastic leukemia/lymphoblastic lymphoma who develop allergy/silencing inactivation of E.
-
Blood: Tigrelor prophylaxis does not reduce vascular occlusive crisis in children with sickle cell disease
Time of Update: 2022-10-12
The Phase 3 HESTIA3 study aimed to evaluate the efficacy and safety of the reversible P2Y12 inhibitor tigrelor vs placebo in preventing vascular occlusive crisis in children with sickle cell disease.
-
Iron tetra iron deficiency anemia four brothers
Time of Update: 2022-10-12
elevated serum TIBC:Iron anemia, acute hepatitis, etcDecreased serum TIBC:Cirrhosis, nephropathy, uremia and hemochromatosisIron four-item combined test Iron deficiency anemia is the most common type of anemia and is a small cell hypochromic anemia caused by insufficient iron storage in the body affecting hemoglobin synthesis.
-
Blood Routine Test Experience Sharing - Interesting Scatter Plot
Time of Update: 2022-10-12
02 Case passedIn the daily blood routine result review, the author encountered a patient specimen with a malignant tumor of the liver, and the abnormal scatter in the lower left corner of the patient's white blood cell scatter map increased significantly.
-
Front Oncol: Correlation between clinical and circulatory metabolic biomarkers and constitutional and functional impairment in chronic lymphocytic leukemia in adults
Time of Update: 2022-10-12
In the univariate analysis of clinical factors, a longer period of time since diagnosis is associated with a higher likelihood of aerobic fitness for dysfunction (OR = 3.
-
[CLEAR Currier a daily case] thalassemia
Time of Update: 2022-10-12
Chest mass is usually seen in patients with thalassemia or congenital hemolytic anemia3.
Chest mass is usually seen in patients with thalassemia or congenital hemolytic anemia3.
Chest mass is usually seen in patients with thalassemia or congenital hemolytic anemia3.
-
J Clin Med.: Are brain networks less efficient in young survivors of acute lymphoblastic leukemia? Evidence from individual morphological brain network analysis
Time of Update: 2022-10-12
In one study, the research team constructed a single-subject GM network based on multiple morphological characteristics and multiple Euclidean distances, and applied graph theory analysis to study the connection topology of young survivors of acute lymphoblastic leukemia.
-
Lancet Haematol: Iberdomide plus dexamethasone for relapsed/refractory multiple myeloma
Time of Update: 2022-10-12
This multi-cohort, open-label Phase 1/2 trial in Europe, Canada, and the United States enrolled multiple myeloma patients aged 18 years and older who had received at least second-line treatment, including lenalidomide or pomatomide and proteasome inhibitors.
-
Bewildering plasma cells
Time of Update: 2022-10-12
Myelodysis is low, the granules are predominantly non-hematopoietic, the three lines of cells are significantly reduced, mature lymphocytes and plasma cells are increased, biopsy shows extremely low hyperplasia, other secondary bone marrow failure is excluded, and AA is temporarily considered.
-
Ther Adv Hematol: Infection is associated with myelodysplastic syndrome, chronic myeloid monocytic leukemia, and prognosis in patients with acute myeloid leukemia treated with hypomethylation drugs
Time of Update: 2022-10-12
The researchers obtained data from 412 unselected serial patients in 23 Spanish hospitals who were diagnosed with high-risk myelodysplastic syndrome, chronic monocytic leukemia or acute myeloid leukemia and received HMA treatment.
-
NEJM: GPRC5D-targeted CAR-T cell therapy for multiple myeloma treatment
Time of Update: 2022-10-12
In this Phase 1 dose-increasing study, we performed GPRC5D-targeted CAR T cell therapy (MCARH109) at four dose levels for patients with multiple myeloma who had undergone extensive pretreatment, including those who relapsed after BCMA CAR T cell therapy.
-
【Focus on the frontier】AI diagnosis of acute promyelocytic leukemia
Time of Update: 2022-10-12
To avoid these early deaths, early initiation of treatment is recommended, so a quick and accurate diagnosis is key to reducing early mortality in APL.
To avoid these early deaths, early initiation of treatment is recommended, so a quick and accurate diagnosis is key to reducing early mortality in APL.
-
Application of Delarosx film-coated tablets in pediatric patients with transfusion-dependent thalassemia: a single-center experience
Time of Update: 2022-10-12
In terms of efficacy, the findings confirm that DFX FCT has a preventive effect on iron loading in the liver and heart, however, in order to ensure adequate chelation, higher doses are required than generally recommended.
